Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Immune Checkpoint Inhibitors
99%
Melanoma
66%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
62%
Programmed Death-ligand 1 (PD-L1)
49%
Immune-related Adverse Events
48%
T-cell Mediated
38%
Teff
35%
High Risk
28%
Metastatic Melanoma
26%
Tumor Growth
25%
Cancer Immunotherapy
25%
Melanocytic Tumor
25%
Anti-PD-1 Therapy
25%
Checkpoint Blockade
24%
Endocrine Therapy
24%
Tumor Microenvironment
24%
Antitumor Activity
23%
Synergize
23%
CD8+ T Cells
23%
Checkpoint Blockade Therapy
23%
Anti-cytotoxic
21%
Tumor Immunity
21%
Myasthenia Gravis
21%
Cardiomyocytes
21%
Immune Checkpoint Inhibitor Treatment
20%
Tumor
20%
Graft-versus-host Disease (GvHD)
19%
IL-6 Blockade
19%
Immunotherapy Toxicity
19%
Transradial Catheterization
19%
Aldesleukin
19%
NKTR-214
19%
Antiphospholipid Antibodies
19%
Tumor Lysis Syndrome
19%
Immune Checkpoint Blockade
19%
Solid Tumors
19%
Mesp1
19%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
19%
Post-transplantation Cyclophosphamide (PTCy)
19%
Kinase Insert Domain Receptor
19%
Atezolizumab
19%
Grover Disease
19%
Myelodysplastic Syndrome
19%
Acute Myeloid Leukemia
19%
Conditional Knockout
19%
Immune Suppression
19%
Systematic Literature Review
19%
Cell Repair
19%
Mouse Heart
19%
Treatment Outcome
19%
Medicine and Dentistry
Immune Checkpoint Inhibitor
83%
Melanoma
76%
T Cell
60%
CTLA-4
59%
Neoplasm
46%
Cytotoxic T-Cell
43%
Immune-Related Adverse Events
43%
Cancer Therapy
38%
Specific Tumor
33%
Programmed Death 1 Ligand 1
29%
Cancer Immunotherapy
24%
Tumor Progression
24%
Myasthenia gravis
20%
Immunotherapy
20%
Cell Regeneration
19%
Interleukin 2
19%
Severe Acute Respiratory Syndrome Coronavirus 2
19%
COVID-19
19%
Allogeneic Hematopoietic Stem Cell Transplantation
19%
Cyclophosphamide
19%
Antineoplastic Activity
19%
Bone Morphogenetic Protein 2
19%
Cardiac Muscle Cell
19%
Systematic Review
19%
Cardiovascular System
19%
Tumor Lysis Syndrome
19%
Mesoderm
19%
Progenitor Cell
19%
Acute Graft Versus Host Disease
19%
Biological Therapy
19%
Acute Myeloid Leukemia
19%
Atezolizumab
19%
Transient Acantholytic Dermatosis
19%
Hormone Therapy
19%
Breast Cancer
19%
Myelodysplastic Syndrome
19%
Heart Left Atrium Pressure
19%
Immunosuppressive Treatment
19%
Tumor Model
19%
Catheterization
19%
Interleukin 6 Receptor
19%
Vasculotropin Receptor 2
19%
CD8 Antigen
19%
Skin Toxicity
19%
Germ Cell
19%
Lymphocyte
19%
Tumor Vaccine
19%
Treatment Outcome
19%
Artificial Intelligence
19%
Graft Versus Host Reaction
17%
Pharmacology, Toxicology and Pharmaceutical Science
Immune Checkpoint Inhibitor
100%
Immunotherapy
58%
Neoplasm
57%
Malignant Neoplasm
51%
Cytotoxic T Lymphocyte Antigen 4
37%
Melanoma
34%
Adverse Event
31%
CD8 Antigen
29%
Programmed Death 1 Ligand 1
25%
Solid Malignant Neoplasm
20%
Myasthenia gravis
20%
Antiphospholipid Antibody
19%
Interleukin 6 Receptor
19%
Glycoprotein Gp 100
19%
Atezolizumab
19%
Observational Study
19%
Transient Acantholytic Dermatosis
19%
Acute Myeloid Leukemia
19%
Myelodysplastic Syndrome
19%
Tumor Lysis Syndrome
19%
Cyclophosphamide
19%
Interleukin 2
19%
Acute Graft Versus Host Disease
19%
Skin Toxicity
19%
Tumor Vaccine
19%
Graft Versus Host Reaction
19%
Breast Cancer
19%
Ipilimumab
18%
Metastatic Melanoma
15%
Antitumor Activity
14%
Side Effect
12%
Lung Cancer
12%
Thromboembolism
11%
Tumor Antigen
10%
Urogenital Tract Cancer
9%
Dermatological Agent
9%
Cytokine
9%
Combination Therapy
9%
Digestive System Cancer
8%
Freund's Adjuvant
7%
Disease Course
7%
Overall Survival
6%
Monoclonal Antibody
6%
Programmed Cell Death
6%
Transitional Cell Carcinoma
6%